Respiratory News and Research RSS Feed - Respiratory News and Research

‘Concerning’ rise in pneumococcus risk factors

‘Concerning’ rise in pneumococcus risk factors

Researchers report that the incidence of Streptococcus pneumoniae infection has fallen significantly in the USA in the past decade but describe a “concerning trend” whereby the baseline health status of those with serious pneumococcal disease has worsened. [More]
New blood test provides fast, accurate diagnosis of tuberculosis in children

New blood test provides fast, accurate diagnosis of tuberculosis in children

A new blood test provides a fast and accurate tool to diagnose tuberculosis in children, a new proof-of-concept study shows. The newly developed test (TAM-TB assay) is the first reliable immunodiagnostic assay to detect active tuberculosis in children. [More]
Wockhardt receives coveted QIDP status from FDA for WCK 771 and WCK 2349 drugs

Wockhardt receives coveted QIDP status from FDA for WCK 771 and WCK 2349 drugs

Wockhardt Limited today announces a major boost to the New Drug Discovery program in Anti-Infective research when two of its drugs, WCK 771 and WCK 2349, received the coveted Qualified Infectious Disease Product (QIDP) status from U.S. Food & Drug Administration. [More]
New paper highlights ways to improve outcomes of Ebola virus infection

New paper highlights ways to improve outcomes of Ebola virus infection

The largest-ever Ebola virus disease outbreak is ravaging West Africa, but with more personnel, basic monitoring, and supportive treatment, many of the sickest patients with Ebola virus disease do not need to die, note the authors of a new paper published ahead of print publication in the American Thoracic Society's American Journal of Respiratory and Critical Care Medicine. [More]
Researchers reveal transmission rate of MERS coronavirus

Researchers reveal transmission rate of MERS coronavirus

The MERS coronavirus has caused disease outbreaks across the Arabian Peninsula and spread to Europe several times. The severe pneumonia virus has claimed the lives of several hundred people since its discovery in 2012. [More]
InnoPharma receives FDA approval for generic DACOGEN

InnoPharma receives FDA approval for generic DACOGEN

InnoPharma, Inc. today announced the approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for decitabine for injection, a generic version of Eisai Inc.'s DACOGEN. [More]
CHLA ECMO program honored with prestigious Award for Excellence in Life Support

CHLA ECMO program honored with prestigious Award for Excellence in Life Support

The Extracorporeal Membrane Oxygenation program at Children's Hospital Los Angeles has been honored for the third time with the prestigious Award for Excellence in Life Support by the Extracorporeal Life Support Organization, an international group of health care professionals and scientists who evaluate hospital treatment therapies for patients fighting complex cardiac disease and respiratory failure. [More]
New treatment fights respiratory syncytial virus

New treatment fights respiratory syncytial virus

The New England Journal of Medicine published research results on Aug. 21 from a clinical trial of a drug shown to safely reduce the viral load and clinical illness of healthy adult volunteers intranasally infected with respiratory syncytial virus (RSV). [More]
School nurses reach 98% of students in U.S. public schools to diagnose primary immunodeficiency

School nurses reach 98% of students in U.S. public schools to diagnose primary immunodeficiency

School nurses reach 98 percent of the 50,000,000 students in U.S. public schools, grades k-12, and are uniquely positioned to facilitate the early diagnosis of serious medical conditions such as primary immunodeficiency (PI). [More]
Bacteremia linked to worse in-hospital course, outcomes in patients with pneumonia

Bacteremia linked to worse in-hospital course, outcomes in patients with pneumonia

The presence of bacteremia in patients with pneumonia is associated with a worse in-hospital course of illness and poorer patient outcomes, show Spanish findings. [More]
Respiratory infection control measures being adopted for Ebola patients are unnecessary and may heighten public panic

Respiratory infection control measures being adopted for Ebola patients are unnecessary and may heighten public panic

Respiratory infection control measures – which have been adopted by most health agencies to deal with the Ebola epidemic in west Africa – are unnecessary, and may heighten panic and fear among the public, according to the authors of a new letter, published in The Lancet, and written by Professor Jose M. Martin-Moreno from the University of Valencia in Spain, and colleagues. [More]
Report on Co-development Terms & Agreements in Pharma, Biotech and Diagnostics

Report on Co-development Terms & Agreements in Pharma, Biotech and Diagnostics

The Co-development Terms and Agreements in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the co-development deals and agreements entered into by the worlds leading life science companies. [More]
New MS treatment found safe, tolerable in phase I clinical trials

New MS treatment found safe, tolerable in phase I clinical trials

A new treatment under investigation for multiple sclerosis (MS) is safe and tolerable in phase I clinical trials, according to a study published August 27, 2014, in Neurology Neuroimmunology & Neuroinflammation, a new online-only, freely accessible, specialty medical journal. [More]
High dew point triggers air quality alert for dangerous levels of mold in the Midwest

High dew point triggers air quality alert for dangerous levels of mold in the Midwest

The heavy rains, hot temperatures and high dew point have triggered an air quality alert for dangerous levels of mold in the Midwest. "The interior mold exposure for homes experiencing flooding or water seepage will be even more toxic," warns Joseph Leija, MD, allergist who performs the Gottlieb Allergy Count, the official daily allergy count for the Midwest. [More]
Recommendation by physician could halve racial disparity in who gets flu shot

Recommendation by physician could halve racial disparity in who gets flu shot

Doctors should make a point of offering a flu vaccine to their patients. A simple reminder could considerably reduce the number of racial and ethnic minorities who currently do not vaccinate themselves against this common contagious respiratory illness. [More]
Actavis files ANDA for generic version of Neupro

Actavis files ANDA for generic version of Neupro

Actavis plc today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Rotigotine Extended-release Transdermal Film, 1 mg/24 hr, 2mg/24 hr, 3 mg/24hr, 4 mg/24 hr, 6mg/24hr, and 8 mg/24 hr. [More]
Ohio State, Nationwide Children's Hospital partner with ENTvantage for diagnosing bacterial sinusitis

Ohio State, Nationwide Children's Hospital partner with ENTvantage for diagnosing bacterial sinusitis

The Ohio State University, through the Ohio State Innovation Foundation, and Nationwide Children's Hospital announced the signing of an exclusive, world-wide agreement with ENTvantage Diagnostics Inc. licensing a technology for rapid diagnosing of bacterial sinusitis. [More]
Study links gum disease to lung disease, cancer and heart failure

Study links gum disease to lung disease, cancer and heart failure

Most people are very familiar with the reality that, if they don't practice regular brushing and overall good dental hygiene, they are at risk for developing gum disease. Less well known is the full extent of the potential harm caused by gum disease. [More]
Study suggests that colds may temporarily increase stroke risk in kids

Study suggests that colds may temporarily increase stroke risk in kids

A new study suggests that colds and other minor infections may temporarily increase stroke risk in children. The study is published in the August 20, 2014, online issue of Neurology®, the medical journal of the American Academy of Neurology. [More]
FDA approves GlaxoSmithKline’s Arnuity Ellipta for treatment of asthma

FDA approves GlaxoSmithKline’s Arnuity Ellipta for treatment of asthma

GlaxoSmithKline plc today announced that the FDA has approved Arnuity™ Ellipta® (fluticasone furoate inhalation powder), a once-daily inhaled corticosteroid (ICS) medicine for maintenance treatment of asthma as prophylactic therapy in patients aged 12 years and older. Arnuity is not indicated for relief of acute bronchospasm. [More]